Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib

Haematologica

Volumn 96, Issue 10, 2011, Pages 1457-1461

  Breccia, Massimo ^a   Latagliata, Roberto ^a   Stagno, Fabio ^b   Luciano, Luigiana ^c   Gozzini, Antonella ^d   Castagnetti, Fausto ^e   Fava, Carmen ^f   Cavazzini, Francesco ^g   Annunziata, Mario ^h   Rossi, Antonella Russo ⁱ   Pregno, Patrizia ^j   Abruzzese, Elisabetta ^k   Vigneri, Paolo ^b   Rege Cambrin, Giovanna ^f   Sica, Simona ^l   Pane, Fabrizio ^c   Santini, Valeria ^d   Specchia, Giorgina ⁱ   Rosti, Gianantonio ^e   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Ospedale Ferrarotto   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f Ematologia Polo Universitario ASO San Luigi Gonzaga   (Italy)

^g UNIVERSITY OF FERRARA   (Italy)

^h CARDARELLI HOSPITAL   (Italy)

ⁱ UNIVERSITY OF BARI   (Italy)

^j MOLINETTE HOSPITAL   (Italy)

^k S EUGENIO HOSPITAL   (Italy)

^l CATHOLIC UNIVERSITY   (Italy)

more..

Author keywords

Adult comorbidity evaluation 27 (ACE 27); Charlson comorbidity index; Chronic myeloid leukemia; Dasatinib

Indexed keywords

DASATINIB; IMATINIB;

ADULT COMORBIDITY EVALUATION 27; AGED; ARTICLE; BLOOD TOXICITY; CHARLSON COMORBIDITY INDEX; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUTROPENIA; PATIENT COMPLIANCE; PLEURA EFFUSION; PREDICTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INCIDENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MEDICATION ADHERENCE; PLEURAL EFFUSION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RETROSPECTIVE STUDIES; THIAZOLES; TREATMENT OUTCOME;

EID: 80053634632     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.041251     Document Type: Article

References (17)

1. Deininger MW, O'Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood. 2009;114:1126.
2. Jabbour E, Cortes J, Kantarjian H. Dasatinib for the treatment of Philadelphia chromosome- positive leukemias. Expert Opin Investig Drugs. 2007;16(5):679-87.
3. Steinberg M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome postive acute lymphoblastic leukemia. Clin Ther. 2007;29(11):2289-308.
4. Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer. 2010;116 (2):377-86.
5. Shah NP, Kantarjian H, Kim DW, Rea D, Dorlhiac-Llacer PE, Milone JH, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic phase chronic myeloid leukemia. J Clin Oncol. 2008;26 (19):3204-12.
6. Quintas-Cardama A, Kantarjian H, O'Brien S, Borthakur G, Bruzzi J, Munden R, Cortes J. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25(25): 3908-14.
7. de Lavallade H, Punnialingam S, Milojkovic D, Bua M, Korashad JS, Gabriel IH, et al. Pleural effusions in patients with chronic myeloid leukemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol. 2008;141(5): 745-7.
8. Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. J Cron Dis 1970; 23: 455-68.
9. Breccia M, Frustaci AM, Cannella L, Stefanizzi C, Latagliata R, Cartoni C, et al. Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukemia patients. Hematol Oncol. 2009;27(3):148-53.
10. Birim O, Kappetein AP, Bogers AJJC. Charlson comorbidity index as a predictor of long-term outcome after surgery for nonsmall cell lung cancer. Eur J Cardiothorac Surg. 2005;28(5):759-62.
11. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B. Hematopoietic cell transplantation (HCT)- specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912-19.
12. Baccarani M, Saglio G, Goldman JM, Hochhaus A, Simonsson B, Appelbaum F, et al. European LeukemiaNet. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108 (6):1809-20.
13. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of real-time quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia- a Europe Against Cancer program. Leukemia. 2003;17(12): 2318-57.
14. Mauro MJ. Appropriate sequencing of tyrosine kinase inhibitors in chronic myelogenous leukemia: when to change? A perspective in 2009. Curr Opin Hematol. 2009; 16(2):135-39.
15. Breccia M, Alimena G. Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development. Expert Opin Drug Safety. 2010;9(5):713-21.
16. Khoury HJ, Cortes JE, Kantarjian H, Baccarani M, Shah NP, Bradley-Garelik MB, et al. Safety and efficacy of dasatinib vs imatinib by baseline comorbidity in patients with chronic myeloid leukemia in chronic phase (CML-CP): analysis of the DASISION trial. Blood. 2010;116:3421.
17. Guilhot F, Kantarjian H, Shah NP, Hochhaus A, Bradley-Garelik MB, Dejardin D, Cortes JE. Dasatinib (versus imatinib) in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): analysis of safety and efficacy by use of baseline medications in the DASISION trial. Blood. 2010;116:2295.